We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Expression of drug targets in patients treated with sorafenib, carboplatin and paclitaxel.
- Authors
Jilaveanu, Lucia B; Zhao, Fengmin; Zito, Christopher R; Kirkwood, John M; Nathanson, Katherine L; D'Andrea, Kurt; Wilson, Melissa; Rimm, David L; Flaherty, Keith T; Lee, Sandra J; Kluger, Harriet M
- Abstract
Sorafenib, a multitarget kinase inhibitor, targets members of the mitogen-activated protein kinase (MAPK) pathway and VEGFR kinases. Here we assessed the association between expression of sorafenib targets and biomarkers of taxane sensitivity and response to therapy in pre-treatment tumors from patients enrolled in ECOG 2603, a phase III comparing sorafenib, carboplatin and paclitaxel (SCP) to carboplatin, paclitaxel and placebo (CP).
- Publication
PloS one, 2013, Vol 8, Issue 8, pe69748
- ISSN
1932-6203
- Publication type
Journal Article
- DOI
10.1371/journal.pone.0069748